Trial Profile
A Phase I Trial of AT13387 in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Onalespib (Primary)
- Indications Head and neck cancer; Human papillomavirus infections; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- 16 Oct 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Sep 2020.
- 13 Dec 2018 Planned primary completion date changed from 30 Sep 2018 to 30 Sep 2019.
- 15 Sep 2017 Planned primary completion date changed from 31 May 2017 to 30 Sep 2018.